Navigation Links
Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain,Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the,Knee

- Pain Reductions Observed at Eight Weeks Sustained up to 12 Weeks and Drug Remains Very Well Tolerated -

SOUTH SAN FRANCISCO, Calif., July 02, 2007 /PRNewswire-FirstCall/ -- Anesiva, Inc. today announced preliminary longer-term, follow-up results from a Phase 2 study showing that a 1mg treatment with Adlea(TM) (formerly 4975) in patients with moderate-to-severe osteoarthritis of the knee produced substantial reductions in pain that persisted for up to 12 weeks.

"The positive preliminary results from this knee pain study further strengthen our belief that Adlea will prove to be a safe and effective drug in multiple osteoarthritis indications," said John P. McLaughlin, chief executive officer of Anesiva. "We are on-track to advance Adlea into late-stage trials in various indications this summer, including a Phase 2/3 trial for osteoarthritis of the knee."

Fifty-five patients with osteoarthritis of the knee were randomized to receive either: (I) a single injection of 1 mg of Adlea (n=36) or (II) three stepped ascending weekly doses totaling 1 mg of Adlea (n=19). At baseline prior to treatment, approximately three quarters of the patients had moderate pain while the other quarter had severe or extreme pain. As was previously reported, patients treated with Adlea demonstrated a 61 percent reduction in mean pain intensity from baseline to week one, and the analgesic effect was sustained at all subsequent weeks to the last scheduled in-clinic assessment at week eight, at which time a 64 percent reduction in pain from baseline was reported. At week 12, pain reductions were sustained. A cohort of 50 patients showed a 65 percent reduction from baseline pain scores. Forty two percent of the patients reported "no pain," 44 percent had "mild pain," and only 14 percent reported "moderate" or "severe" pain. The lengthy duration of clinical benefit is consistent with the known mechanism of action that suggests treatment with Adlea administered as a single injectio
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:3/27/2015)... 2015 As of February, InControl Medical, ... for women. "Shipping thousands of our ... is the hundreds of letters, emails and phone ... been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution for ...
(Date:3/27/2015)...   Hospira, Inc. (NYSE: HSP ... world,s leading provider of injectable drugs and infusion ... of biosimilarity of its proposed biosimilar, Epoetin Hospira, ... conditionally approved name of RETACRIT™, compared to the ... data were presented at the National Kidney Foundation ...
(Date:3/27/2015)... 27, 2015  Johnson & Johnson (NYSE: JNJ ) ... (Eastern Time) on Thursday, April 23, 2015, from the State ... Investors and other interested parties may access the live ... at www.jnj.com and clicking on the webcast icon. ... be made available a few hours after the live meeting ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
... Inc. (Nasdaq: MYL ) CEO Heather Bresch today ... Committee at a hearing hosted by the subcommittee on Health ... Fees and Further Examination of Drug Shortages." In ... of mind in knowing that every prescription, brand or generic, ...
... Mass., Feb. 9, 2012 Syndax Pharmaceuticals, ... that scientists at Roswell Park Cancer Institute have ... inhibitor of class I histone deacetylases, has novel ... of cancer immunotherapies in models of renal and ...
Cached Medicine Technology:Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 2Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 3Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 4Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models 2Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models 3
(Date:3/28/2015)... 28, 2015 How best to treat ... field in orthopaedic medicine. While diagnostic hip injections are ... the pain etiology, research presented today at the American ... Day suggests that pain relief from this diagnostic injection ... , “Our study looked to assess if the ...
(Date:3/28/2015)... NC (PRWEB) March 28, 2015 Genomic ... with peritoneal mesothelioma, revealing, for the first time, key ... Click here to read the newly posted story ... at the University of British Columbia, the British Columbia ... genome mapping to reveal underlying molecular alterations and mutations ...
(Date:3/28/2015)... 2015 Aureus Medical Group (web: ... physical therapy jobs, has announced that it will ... Therapy Association Annual Conference to be held April ... in Columbus, OH. , The OPTA Annual ... with products and services. , Representatives from ...
(Date:3/28/2015)... Viejo, California (PRWEB) March 28, 2015 ... announced a new overlay entitled Scratches 5K from Pixel ... grungy scratch effects to any media inside Final Cut ... Studios. “StoryBoard Corporate saves time and is an effective ... media using FCPX Overlay Scratches 5K's intuitive grunge overlays. ...
(Date:3/28/2015)... CA (PRWEB) March 28, 2015 ... specialists , this week released a report about the ... symptoms of asthma sufferers, and according to recent medical ... , According to the Environmental Protection Agency, people ... asthmatic reactions. Breathing in mold may trigger asthma attacks ...
Breaking Medicine News(10 mins):Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3
... , NEW YORK, Aug. 14 MS ... conducted by AstraZeneca, found that while most patients with asthma ... act accordingly. , , "This finding ... asthma and the necessary steps people should take to achieve ...
... ... present a technology and admissions educational session for THCA members , ... Atlanta, GA (PRWEB) August 14, 2009 ... providers, announced today that it will present a session at the Tennessee Health Care ...
... ... collision avoidance method used in uncontrolled areas, risks inherent in such situations , ... San Mateo, CA (Lexis Nexis) August 14, ... August 8th, in which nine people were killed when a small aircraft collided in midair ...
... , SACRAMENTO, Calif., Aug. 13 The ... million to the Healthy Families Program today to cover health care costs ... due to the state,s fiscal crisis. The funding, approved at a special ... 0-5 through June 2010. , , "In the current ...
... ... of Sexual Health in His New Book ,Ultimate Sexual Health & Performance, , ... Los Angeles, California (Vocus) August 13, 2009 ... his book ,Ultimate Sexual Health & Performance., Bringing over 35 years of research and ...
... , , JACKSON, Miss., Aug. 13 ... benefits for speech therapy services, The Mississippi School Boards Association and ... the new Medicaid claiming policy for the coming school year . ... by school providers, which are in fact still claimable. Specifically, ...
Cached Medicine News:Health News:Keeping Asthma Under Control 2Health News:Patient Placement Systems Presents a Session at the THCA 2009 Annual Convention 2Health News:Patient Placement Systems Presents a Session at the THCA 2009 Annual Convention 3Health News:Midair Collision over Hudson Provides Tragic Reminder that Airplanes and Helicopters Don't Mix Well, According to Aviation Law Expert 2Health News:First 5 California Approves $81.4 Million Contribution to Help Restore Healthy Families Program's Viability 2Health News:Definitive Sexual Health Book Released 2Health News:Definitive Sexual Health Book Released 3Health News:Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 2Health News:Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 3
... control is designed for monitoring human urine ... routine and stat testing and meets CLIA ... are included for most frequently tested analytes. ... chemistry analyzers including: Aeroset, AU Series, Cobas, ...
... control validates urine dipstick readings by applying ... a plastic dropper tip designed for easy ... is the addition of creatinine and microalbumin. ... qualitative results for hCG for early pregnancy ...
... quanTtest human protein standards are available in ... and 200 mg/dL and are packaged in ... ready-to-use, requiring no reconstitution or dilution and ... purified human albumin and human globulin at ...
... is a completely new concept ... use of optic technology for ... applying touch-less vibration system (Patent ... ergonomic user friendly, novel design ...
Medicine Products: